Between-trial heterogeneity in ARDS research
Por um escritor misterioso
Descrição
Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes - The Lancet
Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019 - eClinicalMedicine
Acute respiratory distress syndrome in adults: diagnosis, outcomes, long-term sequelae, and management - The Lancet
Strategies to minimize heterogeneity and optimize clinical trials in Acute Respiratory Distress Syndrome (ARDS): Insights from mathematical modelling - ScienceDirect
Designing an ARDS trial for 2020 and beyond: focus on enrichment strategies
Strategies to minimize heterogeneity and optimize clinical trials in Acute Respiratory Distress Syndrome (ARDS): Insights from mathematical modelling - eBioMedicine
Frontiers Mechanism of COVID-19 Causing ARDS: Exploring the Possibility of Preventing and Treating SARS-CoV-2
Frontiers Pharmacologic therapies of ARDS: From natural herb to nanomedicine
PLATFORM TECHNOLOGY - Predictive Medicine, Biomarkers & the Multiple Unmet Needs in Acute Respiratory Distress Syndrome
Identification of early and intermediate biomarkers for ARDS mortality by multi-omic approaches
Frontiers Gene Therapy for Acute Respiratory Distress Syndrome
Towards a biological definition of ARDS: are treatable traits the solution?, Intensive Care Medicine Experimental
Heterogeneity of Ventilation/Perfusion Mismatch at Different Levels of PEEP and in Respiratory Mechanics Phenotypes of COVID-19 ARDS
Membranes, Free Full-Text
Overview of the analysis plan and study design. ALVEOLI = Assessment of
de
por adulto (o preço varia de acordo com o tamanho do grupo)
